These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14694839)

  • 21. Acarbose for patients with hypertension and impaired glucose tolerance.
    Kaiser T; Sawicki PT
    JAMA; 2003 Dec; 290(23):3066; author reply 3067-9. PubMed ID: 14679260
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 23. Individualizing glycemic targets in type 2 diabetes mellitus.
    Aron D; Conlin PR; Hobbs C; Vigersky RA; Pogach L
    Ann Intern Med; 2011 Sep; 155(5):340-1. PubMed ID: 21893635
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
    Hanefeld M; Cagatay M; Petrowitsch T; Neuser D; Petzinna D; Rupp M
    Eur Heart J; 2004 Jan; 25(1):10-6. PubMed ID: 14683737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.
    Kim HJ; Kim DJ
    J Diabetes Investig; 2017 Jul; 8(4):431-433. PubMed ID: 27930863
    [No Abstract]   [Full Text] [Related]  

  • 27. [Revised blood pressure goals and no elevated glucose readings in between].
    MMW Fortschr Med; 2005 Dec; 147(51-52):72. PubMed ID: 16402718
    [No Abstract]   [Full Text] [Related]  

  • 28. [New studies, new strategies, new guidelines: so that diabetic patients will live longer].
    Aumiller J
    MMW Fortschr Med; 2005 Oct; 147(41):4-6. PubMed ID: 16270500
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo.
    Calle-Pascual A; Garcia-Honduvilla J; Martin-Alvarez PJ; Calle JR; Maranes JP
    Diabetes Metab; 1996 Jun; 22(3):201-2. PubMed ID: 8697309
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system.
    Rosak C; Mertes G
    Curr Diabetes Rev; 2009 Aug; 5(3):157-64. PubMed ID: 19689250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
    Marcus AO
    Diabetes Technol Ther; 2000; 2(2):275-81. PubMed ID: 11469270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
    Roze S; Valentine WJ; Evers T; Palmer AJ
    Curr Med Res Opin; 2006 Jul; 22(7):1415-24. PubMed ID: 16834840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Arterial risk in type 2 diabetes: from mega-trials to prescription].
    Bonnet F; Moulin P
    Rev Prat; 2003 May; 53(10):1095-101. PubMed ID: 12846030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
    Hanefeld M; Schaper F
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postprandial hyperglycaemia and cardiovascular disease.
    Yudkin JS
    Diabet Med; 2006 Mar; 23 Suppl 1():24-5; author reply 25-6. PubMed ID: 16483262
    [No Abstract]   [Full Text] [Related]  

  • 39. Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point?
    Goodarzi MO; Psaty BM
    JAMA; 2008 Nov; 300(17):2051-3. PubMed ID: 18984894
    [No Abstract]   [Full Text] [Related]  

  • 40. No evidence for a reduction of myocardial infarctions by acarbose.
    van de Laar FA; Lucassen PL
    Eur Heart J; 2004 Jul; 25(13):1179; author reply 1179-80. PubMed ID: 15231377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.